Annis Marney is an Endocrinology/Metabolic physician affiliated with Tennessee Oncology. OpenAlex indexes 28 publications with 1,248 citations (h-index 10); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
330 23rd Ave N
Suite 500
Nashville, TN 372031534
Telephone
615-342-5900Registry record last updated 9 Feb 2022.
Clinical trials
- Effect of Sitagliptin on Short-Term Metabolic Dysregulation of Oral Glucocorticoid Therapy
Sponsor: University of Vermont
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
64 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Novo Nordisk IncProgram year202530 payments
- Lilly USA, LLCProgram year202522 payments
- Abbott LaboratoriesProgram year202516 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Musculoskeletal
61.3%RANK Ligand Inhibitor61.3%Denosumab100%Part B, office-administered≥42 patientsMetabolism & gastrointestinal
24.3%Insulin Analog8.7%Tresiba Flextouch U-20020%Tresiba Flextouch U-10016%Novolog Flexpen12%Lantus Solostar12%Soliqua 100-335%Toujeo Max Solostar5%Toujeo Solostar5%Humalog Kwikpen U-1004%Humalog4%Humalog Kwikpen U-2004%Insulin Lispro Kwikpen U-1003%Novolog3%Fiasp2%Insulin Lispro2%Lantus2%Part D<11 patientsGLP-1 receptor agonist5.7%Ozempic73%Mounjaro16%Trulicity10%Part D≥62 patients+ 8 more classes in this area
Hormonal (systemic)
9.1%l-Thyroxine7%Levothyroxine Sodium76%Synthroid24%Part D≥112 patientsThyroid Hormone Synthesis Inhibitor1.8%Methimazole100%Part D≥36 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Intermittently scanned CGM in older adults with type 2 diabetes not taking insulin: iMMEDIATE post hoc analysis
Journal of the Endocrine Society
2026 - Remission of Recently Diagnosed Type 2 Diabetes Mellitus With Weight Loss and Exercise
Journal of Cardiopulmonary Rehabilitation and Prevention
2015
Similar KOLs
Other experts from the same institution or the same specialty.
Ian Flinn, MD
Tennessee Oncology
Bipin Savani, MD
Tennessee Oncology
Lester Porter, MD
Tennessee Oncology
Shakthi Bhaskar, MD
Tennessee Oncology
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”